黄芪精口服液治疗儿童心肌炎疗效观察  

Therapeutic efficacy of Huangqijing oral liquid in treatment of myocarditis in children

作　　者：滕彬[1] 

机构地区：[1]云南省文山州人民医院,云南文山663000

出　　处：《心血管病防治知识（学术版）》2015年第9期94-97,共4页Prevention and Treatment of Cardiovascular Disease

摘　　要：目的分析在小儿心肌炎治疗过程中应用黄芪精口服液的临床效果。方法选择2013年1月-2014年1月在我院进行治疗的病毒性心肌炎患儿86例,随机分成治疗组及对照组,每组各43例,对照组采用常规西药心肌炎治疗措施进行治疗,治疗组在对照组治疗方案的基础上加入黄芪精口服液进行治疗,持续治疗7d后对比两组患儿治疗后临床效果。结果经过治疗后,治疗组总有效率约为97.67%(42/43),对照组总有效率约为79.07%(34/43),差异明显,具有统计学意义,P<0.05;治疗组患儿43例在治疗后出现窦性心动过速2例,频发室性早搏1例,室上性心动过速1例,II度以上房室传导阻滞0例;对照组患儿43例中出现窦性心动过速5例,频发室性早搏2例,室上性心动过速2例,II度以上房室传导阻滞3例,对比两组患儿上述数据,差异显著,具有统计学意义,P<0.05;两组患儿治疗后心肌酶谱指标及心功能指标均优于治疗前,差异明显,P<0.05,而且治疗组好转幅度均明显高于对照组,P<0.05;基于心电图恢复正常时间、症状及体征消失时间、平均住院时间,治疗组均优于对照组,P<0.05;两组患儿在治疗期间均未出现肝肾功能异常变化、重度过敏性反应或低血压等严重不良反应。结论在儿童病毒性心肌炎治疗中应用黄芪精口服液,临床疗效良好,不良反应较少,值得临床广泛应用及进一步推广。Objective To analyze the therapeutic efficacy of Huangqijing oral liquid in children with myocarditis. Methods Eighty-six children with viral myocarditis who were admitted to our hospital from January 2013 to January 2014 were equally and randomly divided into treatment group and control group. The children in the control group were treated with routine Western medicine for the treatment of myocarditis and the children in the treatment group with the therapy for the control group combined with Huangqijing oral liquid. Clinical efficacy was compared between the two groups after 7-day continuous treatment. Results After treatment, the overall response rate in the treatment group （42/43, 97.67%） was significantly higher than that in the control group （34/43, 79.07%, P〈0.05）. Adverse events included sinus tachycardia in 2 cases, frequent ventricular premature beats in 1 case, supraventricular tachycardia in 1 case, and no atrioventricular block grade II or more among the 43 children in the treatment group and sinus tachycardia in 5 cases, frequent ventricular premature beats in 2 cases, supraventricular tachycardia in 2 cases, and atrioventricular block grade II or more in 3 cases among the 43 children in the control group; there was a significant difference in the incidence of adverse events between the two groups （P〈0.05）. The levels of myocardial zymogram and cardiac function markers were both significantly improved in the two groups after treatment （P〈0.05）, and the treatment group showed significantly more improvements than the control group （P〈0.05）. The time to recovery of electrocardiogram, time to disappearance of symptoms and signs, and mean length of hospital stay were significantly shorter in the treatment group than in the control group （P 〈0.05）. No adverse events, including abnormal liver and kidney function, severe allergic reaction, and hypotension, occurred in the two groups during treatment. Conclusion Huangqijing oral liquid has good clinical efficacy and causes f

关 键 词：黄芪精口服液 儿科 病毒性心肌炎 

分 类 号：R272[医药卫生—中医儿科学]